SCHEDULE 13G: Highbridge Capital Management Discloses 9.9% Stake in BioAtla, Including Warrants

Highbridge Capital Management, LLC has reported a 9.9% beneficial ownership stake in BioAtla, Inc., including shares issuable upon warrant exercise, as of December 31, 2024.

Summary

• Highbridge Capital Management, LLC, an investment adviser, reported beneficial ownership of 7,349,205 shares of BioAtla, Inc. common stock.
• This represents 9.9% of BioAtla's outstanding common stock, calculated based on 58,024,691 shares outstanding after the Issuer's registered offering.
• The reported ownership includes 4,839,579 shares of Common Stock issuable upon the exercise of warrants directly held by the Highbridge Funds.
• A 9.90% blocker provision in the terms of the Reported Warrants prevents Highbridge from exercising warrants to the extent it would result in beneficial ownership exceeding 9.90% of the outstanding Common Stock.
• Consequently, Highbridge Capital Management is currently unable to exercise all of its Reported Warrants due to this 9.90% blocker.

Sentiment

Score: 7

Explanation: The filing indicates a significant institutional investment in BioAtla, which can be viewed positively as a vote of confidence. However, the 9.9% blocker on warrant exercise introduces a slight limitation on the investor's immediate ability to increase their stake.

Positives

• A significant institutional investor, Highbridge Capital Management, holds a substantial 9.9% stake in BioAtla, indicating a notable investment interest and potential confidence in the company.
• The investment includes a large number of warrants (4,839,579 shares), suggesting a strategic or long-term interest in the company's future performance and potential upside.

Negatives

• The 9.90% blocker provision limits Highbridge Capital Management's immediate ability to fully exercise its warrants and increase its beneficial ownership beyond the 9.9% threshold, potentially restricting its influence or further investment without additional regulatory considerations.

Risks

• The 9.90% beneficial ownership blocker on warrants limits Highbridge Capital Management's ability to fully convert its warrants into common stock, which could impact its future stake or control over the company.

Future Outlook

The document is a beneficial ownership report (Schedule 13G) and does not contain any forward-looking statements or guidance from company management regarding future performance or strategic plans.

Industry Context

This Schedule 13G filing indicates a significant investment by a hedge fund in a biotechnology company. Such filings are common in the biotech sector, where institutional investors often take substantial positions, sometimes including warrants, to gain exposure to potential growth. The 9.9% blocker is a common provision to avoid triggering certain regulatory requirements or shareholder rights plans that apply at higher ownership thresholds.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake can influence market perception and potentially share price. The 9.9% blocker on warrants might be of interest regarding potential future dilution or control dynamics.

Key Dates

Keywords

BioAtla Inc., Highbridge Capital Management, Schedule 13G, beneficial ownership, common stock, warrants, institutional investment, SEC filing, equity stake